Neutricks® Study Results Presented at European College of Veterinary Behavioral Medicine
Madison, Wis (November 22, 2011) Quincy Animal Health, a leader in canine cognitive health, is pleased to announce, Dr. Gary Landsberg, DVM, a board certified veterinary behaviorist and diplomate of the American College of Veterinary Behaviorists, will be presenting research which demonstrates Neutricks®, an apoaequorin based supplement is able to significantly improve cognitive function in senior dogs. The research will be presented Sunday the 27thof November at the 2011 European Veterinary Behavior Meeting annual meeting held by both the European College of Veterinary Behavioral Medicine and the European Society of Veterinary Ethology.
Dr. Landsberg will share data from two different experiments showing the effectiveness of Neutricks® to help domains of cognitive function such as attention, learning, and recall in senior dogs. One of the most significant findings in the study shows Neutricks® outperformed Anipryl® (selegiline), the only approved medication for the control of clinical signs associated with canine cognitive dysfunction syndrome (CDS).
Key findings presented:
-In an object discrimination test of aged beagles (greater than 9 years old), the Neutricks® treated dogs showed significantly more accuracy in
learning than the placebo-controlled treatment group
-The Neutricks® beagles outperformed the control beagles in a task measuring attention using a visual search task with added distracters.
-In the second study, the aged beagles in the Neutricks® group showed more accurate learning and superior attention than the dogs in the selegiline arm.
Lead researcher Dr. Bill Milgram, Ph.D. of CanCog Technologies commented, “These results provide evidence that apoaequorin has cognitively beneficial effects by showing improved performance over a control group in an aged canine model of Alzheimer’s disease.”
Previous audiences have included the “CanCog Conference on Behavior, Cognition and Aging in Companion Animals” in Toronto Canada this past summer as well as American Veterinary Society of Animal Behavior’s annual symposium. This will mark the second time this year that the data will be presented in France. In July researches from around the world caught a glimpse of the study at the Alzheimer’s Association International Conference, in Paris France.
“We really are pleased with the overwhelmingly positive reception the Neutricks® research has received at each conference. It speaks to the true need in the marketplace for an effective tool for aging canines. In particular, the head-to-head data with Anipryl® will give veterinarians confidence to recommend Neutricks® to their clients.” added Dave Merrick, General Manager of Quincy Animal Health.
Interested parties in reviewing the research can contact www.quincyanimalhealth.com/research/.
About the 2011 European Veterinary Behavior Meeting
17th annual congress of the European Society of Veterinary Clinical Ethology (ESVCE) and the 8th Annual Congress of the European College of the Animal Welfare and Behavioral Medicine (ECAWB) is aimed at individuals or organizations currently working in the fields of veterinary behavioral medicine and animal behavior and welfare science.
About Quincy Animal Health
Quincy Animal Health, LLC markets Neutricks®, a new evidence-based chewable supplement for healthy brain aging in the canine senior wellness market. The product uses technology developed by parent company Quincy Bioscience, a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. www.quincyanimalhealth.com.
Media Contact:
Todd Olson
(608) 827-8134
tolson@quincybioscience.com
Tags: